-
Jan 20, 2025 | 
lupus.bmj.com | Yoshiya Tanaka |Yusuke Miyazaki |Shintaro Hirata |Katsuhide Kusaka
In clinical practice, a lupus low disease activity state (LLDAS) has been proposed as an alternative treatment target for patients with SLE. LLDAS is associated with reduced accrual of organ damage and improvements in quality of life. Patients with SLE in LLDAS experienced a residual disease burden, especially in pain and fatigue, that was associated with activity impairment.
-
Jan 6, 2025 | 
nature.com | Martin Pehrsson |Anne-Christine Bay-Jensen |Morten Asser Karsdal |Bent Deleuran |Tue W. Kragstrup |Satoshi KUBO | +2 more
AbstractUnderstanding how inflammatory cytokines influence profibrogenic wound healing responses in fibroblasts is important for understanding the pathogenesis of fibrosis. TNF-α and IL-13 are key cytokines in Th1 and Th2 immune responses, respectively, while TGF-β1 is the principal pro-fibrotic mediator.
-
Sep 1, 2024 | 
nature.com | Satoshi KUBO |Yoshiya Tanaka
Immune health has been considered impossible to assess through the use of traditional biomarkers. The newly devised immune health metric (IHM) integrates diverse biological data to quantify immune function, offering a comprehensive indicator for the evaluation of immune health. The potential of the IHM to distinguish healthy individuals from patients with monogenic or polygenic immune-mediated diseases might lead to revolutionary changes in treatment strategies for rheumatic diseases.
-
Jul 31, 2024 | 
acrjournals.onlinelibrary.wiley.com | Iain B McInnes |Philip Mease |Yoshiya Tanaka |Kitakyushu Japan
INTRODUCTION Psoriatic arthritis (PsA) is a progressive, long-term, chronic inflammatory disease characterized by symptoms affecting a variety of tissues.
-
Jul 27, 2024 | 
arthritis-research.biomedcentral.com | Sae Ochi |Koshiro Sonomoto |Shingo Nakayamada |Yoshiya Tanaka
This study analyzed the factors associated with improvement of HAQ-DI and reduction of subjective pain among RA patients who achieved LDA within 6 months and one year of treatment. The results showed that the pretreatment background and treatment options were both associated with the improvement.
-
Jul 25, 2024 | 
emjreviews.com | Satoshi KUBO |Yoshiya Tanaka
INTRODUCTIONAn ageing society is characterised by the elderly population, classified as individuals aged 65 years or older, constituting ≥7% of the total population. Furthermore, when the ageing rate reaches 14%, the designation shifts to an aged society, and upon reaching 21%, it is termed a super-aged society.
-
Jun 24, 2024 | 
acrjournals.onlinelibrary.wiley.com | Joan T Merrill |Yoshiya Tanaka |David D'Cruz |Karina Vila-Rivera
Supporting Information Filename Description art42926-sup-0001-Disclosureform.pdfPDF document, 478.5 KB Disclosure Form art42926-sup-0002-Supinfo.pdfPDF document, 3.5 MB Appendix S1: Supporting Information
-
Jun 4, 2024 | 
nature.com | Yoshiya Tanaka
AbstractImpaired insulin secretory capacity is associated with high glycemic variability in patients with type 2 diabetes (T2DM). However, there are no existing reports on the association between insulin secretory capacity and time in range (TIR). This retrospective study involved 330 T2DM admitted for diabetes education who underwent intermittently scanned continuous glucose monitoring (isCGM) and had their fasting serum C-peptide immunoreactivity (S-CPR) measured within 5 days of admission.
-
Apr 27, 2024 | 
medrxiv.org | Yoshiya Tanaka |Atsushi Kumanogoh |Tatsuya Atsumi |Tomonori Ishii
COMPETING INTERESTS: YT has received grants from Mitsubishi-Tanabe, Eisai, Chugai, and Taisho; speaker fees and/or honoraria from Eli Lilly, AstraZeneca, Abbvie, Gilead, Chugai, Behringer-Ingelheim, GlaxoSmithKline, Eisai, Taisho, Bristol-Myers Squibb, Pfizer, and Taiho. AK has received grants from Chugai; consulting fees from Eisai; speaker fees and/or honoraria from Asahi Kasei, Astellas, Eisai, GlaxoSmithKline, Chugai, Eli Lilly, Boehringer-Ingelheim, Pfizer, and Bristol-Myers Squibb.
-
Mar 10, 2024 | 
nature.com | Eric F. Morand |Yoshiya Tanaka |Dafna D Gladman
AbstractTyrosine kinase 2 (TYK2) is a member of the JAK kinase family of intracellular signalling molecules. By participating in signalling pathways downstream of type I interferons, IL-12, IL-23 and IL-10, TYK2 elicits a distinct set of immune events to JAK1, JAK2 and JAK3. TYK2 polymorphisms have been associated with susceptibility to various rheumatic diseases including systemic lupus erythematosus and dermatomyositis.
